Recommendations for Off-Label Drug Use in Ophthalmology in China: A Clinical Practice Guideline.

ABSTRACT: Off-label drugs use is widespread in ophthalmology due to the delay in drug approvals and package inserts update. It has been found to vary among different medical institutions in China, leading to safety problems since inappropriate use. Guidance is urgently needed regarding how best to use the drugs for unapproved indications and routes of administration. We aimed to develop an evidence-based guideline to guide off-label drugs used in ophthalmology in China. The practice guideline was developed by the Hospital Pharmacy Professional Committee, Chinese Pharmaceutical Association, following the WHO handbook for guideline development. The guideline was initially registered in the International Practice Guidelines Registry Platform (IPGRP-2021CN096). The clinical questions included in

SUBMITTER: Li G 

PROVIDER: S-EPMC9171102 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature